|
|
Coral Calcium Scientific Evidence
TrueBlue™ is
a rich source of supplemental Calcium, Magnesium and
Trace Minerals. There is a very large body of scientific
research on these elements available through the National
Library of Medicine's online resource, PubMed. Currently
PubMed lists 298,764 articles under the search term
Calcium, 64,051 articles on Magnesium, and 57,990
research papers on Minerals!
A partial list of the reported
benefits of taking supplemental Calcium, Magnesium
and Trace Minerals are
Calcium: osteoporosis, weight loss, colorectal cancer,coronary
heart disease, increased bone mass, high blood pressure,
premenstrual syndrome
Magnesium: hypertension, diabetes mellitus, atherosclerosis,
kidney stones, psychiatric disorders, cancer, sudden
death syndrome, eclampsia, asthma, vascular headaches,
Tourette’s syndrome, migraine headaches, tension
headaches, coronary artery disease, type 2 diabetes,
osteoporosis
Trace
Minerals: atherosclerosis, cardiovascular
disease, blood pressure, glucose tolerance, colorectal
cancer, thyroid function, bone density
|
| |
| Abstracts
on Calcium |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Calcium, vitamin D,
dairy products, and risk of colorectal cancer
in the cancer prevention study II nutrition cohort
(United States).
McCullough ML, Robertson
AS, Rodriguez C, Jacobs EJ, Chao A, Carolyn J,
Calle EE, Willett WC, Thun MJ.
Epidemiology and Surveillance
Research Department, American Cancer Society,
1599 Clifton Rd NE, Atlanta GA, 30309 USA.
OBJECTIVE: Calcium, vitamin
D, and dairy product intake may reduce the risk
of colorectal cancer. We therefore examined the
association between these factors and risk of
colorectal cancer in a large prospective cohort
of United States men and women. METHODS: Participants
in the Cancer Prevention Study II Nutrition Cohort
completed a detailed questionnaire on diet, medical
history, and lifestyle in 1992-93. After excluding
participants with a history of cancer or incomplete
dietary information, 60,866 men and 66,883 women
remained for analysis. During follow-up through
31 August 1997 we documented 421 and 262 cases
of incident colorectal cancers among men and women,
respectively. Multivariate-adjusted rate ratios
(RR) were calculated using Cox proportional hazards
models. RESULTS: Total
calcium intake (from diet and supplements) was
associated with marginally lower colorectal cancer
risk in men and women (RR = 0.87, 95% CI
0.67-1.12, highest vs lowest quintiles, p trend
= 0.02). The association was strongest for calcium
from supplements (RR = 0.69, 95% CI 0.49-0.96
for > or = 500 mg/day vs none). Total vitamin
D intake (from diet and multivitamins) was also
inversely associated with risk of colorectal cancer,
particularly among men (RR = 0.71, 95% CI 0.51-0.98,
p trend = 0.02). Dairy product intake was not
related to overall risk. CONCLUSIONS: Our
results support the hypothesis that calcium modestly
reduces risk of colorectal cancer. Vitamin
D was associated with reduced risk of colorectal
cancer only in men.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
J Womens
Health (Larchmt). 2003 Mar;12(2):173-82.
Diet, body weight, and
colorectal cancer: a summary of the epidemiologic
evidence.
Giovannucci E.
Channing Laboratory, Department
of Medicine, Brigham and Women's Hospital, Boston,
Massachusetts 02115, USA. edward.giovannucci@channing.harvard.edu
Colorectal cancer is the second
leading cause of cancer death in the United States,
and the number of new cases annually is approximately
equal for men and women. Several nutritional factors
are likely to have a major influence on risk of
this cancer. Physical inactivity and excessive
adiposity, especially if centrally distributed,
clearly increase the risk of colon cancer. Hyperinsulinemia
may be an important underlying risk factor. In
conjunction with obesity and physical inactivity,
which induce a state of insulin resistance, certain
dietary patterns that stimulate insulin secretion,
including high intakes of red and processed meats,
saturated and trans-fats, and highly processed
carbohydrates and sugars, may increase the risk
of colon cancer. There is evidence suggesting
that some component of red meat may independently
increase the risk of colorectal cancer, and
some micronutrients may be important as protective
agents. Currently, the evidence is strongest for
folate and calcium. Folate may be especially
important in alcohol drinkers because alcohol
appears to increase the risk, particularly when
folate intake is low. This interaction may be
related to the antifolate properties of alcohol.
In contrast to earlier studies, more recent epidemiologic
studies have generally not supported a strong
influence of dietary fiber or fruits and vegetables,
although these have other health benefits, and
their consumption should be encouraged. The majority
of colon cancers, as well as many other conditions,
may be prevented by lifestyle alterations in the
intake of these nutritional factors, in addition
to other factors, such as smoking.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Dietary influences
on survival after ovarian cancer.
Nagle CM, Purdie
DM, Webb PM, Green A, Harvey PW, Bain CJ.
School of Population Health,
University of Queensland, Brisbane, Australia.
We evaluated the effects of
various food groups and micronutrients in the
diet on survival among women who originally participated
in a population-based case-control study of ovarian
cancer conducted across 3 Australian states between
1990 and 1993. This analysis included 609 women
with invasive epithelial ovarian cancer, primarily
because there was negligible mortality in women
with borderline tumors. The women's usual diet
was assessed using a validated food frequency
questionnaire. Deaths in the cohort were identified
using state-based cancer registries and the Australian
National Death Index (NDI). Crude 5-year survival
probabilities were estimated using the Kaplan-Meier
technique, and adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) were obtained from
Cox regression models. After adjusting for important
confounding factors, a survival advantage was
observed for those who reported higher intake
of vegetables in general (HR = 0.75, 95% CI =
0.57-0.99, p-value trend 0.01 for the highest
third, compared to the lowest third), and cruciferous
vegetables in particular (HR = 0.75, 95% CI =
0.57-0.98, p-value trend 0.03), and among women
in the upper third of intake of vitamin E (HR
= 0.76, 95% CI = 0.58-1.01, p-value trend 0.04).
Inverse associations were also seen with protein
(p-value trend 0.09), red meat (p-value trend
0.06) and white meat (p-value trend 0.07), and
modest positive trends (maximum 30% excess) with
lactose (p-value trend 0.04), calcium and dairy
products. Although much remains to be learned
about the influence of nutritional factors after
a diagnosis of ovarian cancer, our study suggests
the possibility that a diet high in vegetable
intake may help improve survival.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Am J Clin Nutr. 2003 Jun;77(6):1448-52.
Calcium intake,
body composition, and lipoprotein-lipid concentrations
in adults.
Jacqmain M,
Doucet E, Despres JP, Bouchard C, Tremblay A.
Division of Kinesiology
(MJ and AT) and the Department of Food Science
and Nutrition (J-PD), Laval University, Ste-Foy,
Quebec.
BACKGROUND: Recent data suggest
that variations in calcium intake may influence
lipid metabolism and body composition. OBJECTIVE:
The association between daily calcium intake and
body composition and plasma lipoprotein-lipid
concentrations was studied cross-sectionally in
adults from phase 2 of the Quebec Family Study.
DESIGN: Adults aged 20-65 y (235 men, 235 women)
were studied. Subjects who consumed vitamin or
mineral supplements were excluded. Subjects were
divided into 3 groups on the basis of their daily
calcium intake: groups A (< 600 mg), B (600-1000
mg), and C (> 1000 mg). RESULTS: Daily calcium
intake was negatively correlated with plasma LDL
cholesterol, total cholesterol, and total:HDL
cholesterol in women and men after adjustment
for variations in body fat mass and waist circumference
(P < 0.05). In women, a significantly greater
ratio of total to HDL cholesterol (P < 0.05)
was observed in group A than in group C after
correction for body fat mass and waist circumference.
In women, body weight, percentage body fat, fat
mass, body mass index, waist circumference, and
total abdominal adipose tissue area measured by
computed tomography were significantly greater
(P < 0.05) in group A than in groups B and
C, even after adjustments for confounding variables.
Comparable trends were observed in men, but not
after adjustment for the same covariates. CONCLUSION:
A low daily
calcium intake is associated with greater adiposity,
particularly in women. In both sexes, a high calcium
intake is associated with a plasma lipoprotein-lipid
profile predictive of a lower risk of coronary heart
disease risk compared with a low calcium intake.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Steroid
induced osteoporosis: prevention and treatment
[Article in French]
Roux C, Orcel P.
Institut de rhumatologie,
hopital Cochin, centre d'evaluation des maladies
osseuses, 27, rue du Faubourg-Saint-Jacques, 75014,
Paris, France
Purpose. - Corticosteroid induced
osteoporosis (CIO) is the most frequent complication
of long-term corticosteroid therapy, and the most
frequent cause of secondary osteoporosis. New
data from biological, epidemiological and therapeutic
studies provide basis for optimal management of
this bone disease.Main points. - Corticosteroids
are responsible for both quantitative and qualitative
deleterious effects on bone, through their effect
on bone cells, mainly on osteoblasts (with both
a decrease in osteoblast activity and an increase
in apoptosis). Epidemiological studies have shown
an increased risk of fractures related to CIO,
even for low doses, and during the first 6 months
of treatment. Relative risk is 1.3 and 2.6 for
peripheral and vertebral fractures respectively.
Bone mineral density, measured by dual-energy
X-ray absorptiometry, is decreased at spine and
hip; the risk of fracture is higher in CIO as
compared to post-menopausal osteoporosis, for
a similar bone density. Prevention
of CIO needs the use of the minimal efficacious
dose, and treatment of calcium, vitamin
D and gonadal hormones insufficiencies. Patients
at risk of fracture, as post-menopausal women
with prevalent fractures, should receive a bisphosphonate.Perspective.
- It may be possible to reduce the fracture risk
in patients on long-term corticosteroid therapy.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Joint Bone Spine. 2003 Jun;70(3):203-208.
Effects on
bone mineral density of calcium and vitamin D
supplementation in elderly women with vitamin
D deficiency.
Grados F, Brazier
M, Kamel S, Duver S, Heurtebize N, Maamer M, Mathieu
M, Garabedian M, Sebert JL, Fardellone P.
Rheumatology Department,
North Hospital Group, 80054 cedex 1, Amiens, France
Objectives. - Calcium and vitamin
D deficiency is common in older individuals, particularly
those who live in nursing homes, and increases
the risk of osteoporosis and fractures.Methods.
- We conducted a randomized double-blind placebo-controlled
study of combined supplementation with 500 mg
of elemental calcium, as carbonate, and 400 IU
of vitamin D bid for 12 months in women older
than 65 years of age with vitamin D deficiency,
defined as serum 25(OH)D concentrations </=12
ng/ml.Results. - Mean patient age was 75 +/- 7
years, and median daily dietary intakes of calcium
and vitamin D were 697 mg and 66.8 IU in the supplemented
group (n = 95) and 671 mg and 61.8 IU in the placebo
group (n = 97). The median serum 25(OH)D level
was 7.0 ng/ml in both groups, and the medial intact
parathyroid hormone (PTHi) levels were 49 and
48 pg/ml in the supplemented and placebo groups,
respectively. The median increase in serum 25(OH)D
was 22.0 ng/ml in the supplemented group and 4
ng/ml in the placebo group (P < 0.0001), and
the median PTHi decrease was 17 and 5 pg/ml, respectively
(P < 0.0001). The median bone mineral density
increase was significantly greater in the supplemented
group than in the placebo group: +2.98% vs. -0.21%
at L2-L4 (P = 0.0009), +1.19% and -0.83% at the
femoral neck (P = 0.015), +0.86% and -0.56% at
the trochanter (P = 0.015), and +0.99% and +0.11%
for the whole body (P = 0.01). Similarly, the
median decrease in the main bone markers was significantly
greater in the treated group than in the placebo
group: -1.35 &mgr;g/l vs. +0.50 &mgr;g/l
for bone alkaline phosphatase (P = 0.008), -16.6
nmol/mmol creatinine vs. -2.3 nmol/mmol creatinine
for urinary type I amino-terminal telopeptide
(P = 0.001), and -896 pmol/l vs. -201 pmol/l for
serum type I carboxy-terminal telopeptide (P =
0.003). We found no significant differences between
the two groups for serum calcium, although urinary
calcium excretion changed more in the supplemented
group than in the placebo group. In conclusion, bone mass
in older women with vitamin D deficiency increases
significantly at the lumbar spine, femur, trochanter,
and whole body after calcium and vitamin D supplementation
for 1 year, and concomitantly bone markers
improved as vitamin D levels returned to normal.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
S Afr Med J. 2003 Mar;93(3):224-8.
Calcium
supplementation to prevent pre-eclampsia--a systematic
review.
Hofmeyr GJ, Roodt
A, Atallah AN, Duley L.
Effective Care Research
Unit, East London Hospital Complex, University
of the Witwatersrand, Johannesburg/Fort Hare University,
East London, E Cape.
BACKGROUND: Calcium supplementation
during pregnancy may prevent high blood pressure
and preterm labour. OBJECTIVE: To assess the effects
of calcium supplementation during pregnancy on
hypertensive disorders of pregnancy and related
maternal and child adverse outcomes. DESIGN: A
systematic review of randomised trials that compared
supplementation with at least 1 g calcium daily
during pregnancy with placebo. SEARCH STRATEGY:
The Cochrane Pregnancy and Childbirth Group trials
register (October 2001) and the Cochrane Controlled
Trials Register (Issue 3, 2001) were searched
and study authors were contacted. DATA COLLECTION
AND ANALYSIS: Eligibility and trial quality were
assessed. Data were extracted and analysed. MAIN
RESULTS: There was a modest reduction in the risk
of pre-eclampsia with calcium supplementation
(relative risk (RR) 0.68, 95% confidence interval
(CI): 0.57-0.81). The effect was greatest for
women at high risk of hypertension (RR 0.21, 95%
CI: 0.11-0.39) and those with low baseline calcium
intake (RR 0.32, 95% CI: 0.21-0.49). There was
no overall effect on the risk of preterm delivery,
although there was a reduction in risk among women
at high risk of hypertension (RR 0.42, 95% CI:
0.23-0.78). There was no evidence of any effect
of calcium supplementation on stillbirth or death
before discharge from hospital. There were fewer
babies with birthweight < 2,500 g (RR 0.83,
95% CI: 0.71-0.98). In one study, childhood systolic
blood pressure > 95th percentile was reduced
(RR 0.59, 95% CI: 0.39-0.91). CONCLUSIONS: Calcium
supplementation appears to be beneficial for women
at high risk of gestational hypertension and in
communities with low dietary calcium intake. These benefits were confined to several rather
small trials, and were not found in the largest
trial to date, conducted in a low-risk population.
Further research is required.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Adv Neurol. 2003;92:173-8.
Nutritional
and metabolic aspects of stroke prevention.
Spence JD.
Department of Clinical
Neurological Sciences, University of Western Ontario,
Stroke Prevention and Atherosclerosis Research
Centre, Robarts Research Institute, London, Ontario,
Canada.
Epidemiologic evidence, animal
studies, angiographic and ultrasound studies in
humans, and a limited number of clinical trials
suggest that vitamins C and E may be protective
and that folate, B6, and B12, by lowering homocysteine
levels, may reduce stroke. However, these hypotheses
require testing before widespread use of supplementary
vitamins can be generally recommended (62). Clinical
trials under way will test those hypotheses. In
the meantime, it should be understood that the
role of diet is much more important than is widely
recognized. A
diet low in saturated fat and cholesterol, low
in sodium, high in potassium and calcium, and
containing a lot of fruits and vegetables reduces
blood pressure as much as an antihypertensive
drug and in coronary patients is twice as effective
as statin drugs in reducing death and myocardial
infarction. Such a diet can therefore be
confidently recommended as a source not only of
natural proportions of vitamins and antioxidants
but also for benefits that we are only beginning
to define.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Maturitas. 2003 Apr 25;44(4):299-305.
Calcium-vitamin
D3 supplementation is cost-effective in hip fractures
prevention.
Lilliu H, Pamphile
R, Chapuy MC, Schulten J, Arlot M, Meunier PJ.
CLP-Sante, 9-11 rue du
Mont Aigoual, F-75015 Paris, France. herve.lilliu@clp-sante.fr
OBJECTIVE: To assess the cost
implications for a preventive treatment strategy
for institutionalised elderly women with a combined
1200 mg/day calcium and 800 IU/day vitamin D(3)
supplementation in seven European countries. DESIGN:
Retrospective cost effectiveness analysis based
on a prospective placebo-controlled randomised
clinical trial. DATA SOURCES: Recently published
cost studies in seven European countries. Clinical
results from Decalyos, a 3-year placebo-controlled
study in elderly institutionalised women. TRIALS:
Decalyos study, with 36 months follow-up of 3270
mobile elderly women living in 180 nursing homes,
allocated to two groups. One group received 1200
mg/day elemental calcium in the form of tricalcium
phosphate together with 800 IU/day (20 microg)
of cholecalciferol (vitamin D(3)), the other placebo.
RESULTS: In the 36 months analysis of the Decalyos
study, 138 hip fractures occurred in the group
of 1176 women, receiving supplementation and 184
hip fractures in the placebo group of 1127 women.
The mean duration of treatment was 625.4 days.
Adjusted to 1000 women, 46
hip fractures were avoided by the calcium and
vitamin D(3) supplementation. For all countries,
the total costs in the placebo group were higher
than in the group receiving supplementation, resulting in a net benefit of 79000-711000 per
1000 women. CONCLUSION: This analysis suggests
that the supplementation strategy is cost saving.
The results
may underestimate the net benefits, as this treatment
has also shown to be effective in decreasing the
incidence of other non-vertebral fractures in elderly
institutionalised women.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
J Hum Nutr Diet. 2003 Apr;16(2):97-109.
Nutritional management
of rheumatoid arthritis: a review of the evidence.
Rennie KL, Hughes
J, Lang R, Jebb SA.
MRC Human Nutrition Research,
Elsie Widdowson Laboratory, Fulbourn Road, Cambridge,
UK; Independent Nutrition Consultant, 7 Holmesdale
Park, Nutfield, Surrey, UK.
Rheumatoid arthritis (RA) is
a debilitating disease and is associated with
increased risk of cardiovascular disease and osteoporosis.
Poor nutrient status in RA patients has been reported
and some drug therapies, such as nonsteroidal
anti-inflammatory drugs (NSAIDs), prescribed to
alleviate RA symptoms, may increase the requirement
for some nutrients and reduce their absorption.
This paper reviews the scientific evidence for
the role of diet and nutrient supplementation
in the management of RA, by alleviating symptoms,
decreasing progression of the disease or by reducing
the reliance on, or combating the side-effects
of, NSAIDs. Supplementation with long-chain n-3
polyunsaturated fatty acids (PUFA) consistently
demonstrates an improvement in symptoms and a
reduction in NSAID usage. Evidence
relating to other fatty acids, antioxidants, zinc,
iron, folate, other B vitamins, calcium, vitamin
D and fluoride are also considered. The present
evidence suggests that RA patients should consume
a balanced diet rich in long-chain n-3 PUFA and
antioxidants. More randomized long-term
studies are needed to provide evidence for the
benefits of specific nutritional supplementation
and to determine optimum intake, particularly
for n-3 PUFA and antioxidants.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Can Fam Physician. 2002 Nov;48:1789-97.
Premenstrual
syndrome. Evidence-based treatment in family practice.
Douglas S.
Department of Family Medicine,
Dalhousie University, Abbie Lane Bldg, QEII Hospital,
5909 Veterans Memorial Ln, Halifax, NS B3H 2E2.
sue.douglas@dal.ca
OBJECTIVE: To evaluate the
strength of evidence for treatments for premenstrual
syndrome (PMS) and to derive a set of practical
guidelines for managing PMS in family practice.
QUALITY OF EVIDENCE: An advanced MEDLINE search
was conducted from January 1990 to December 2001.
The Cochrane Library and personal contacts were
also used. Quality of evidence in studies ranged
from level I to level III, depending on the intervention.
MAIN MESSAGE: Good
scientific evidence shows that calcium carbonate
(1200 mg/d) and selective serotonin reuptake inhibitors
are effective treatments for PMS. The most
commonly used therapies (including vitamin B6,
evening primrose oil, and oral contraceptives)
are based on inconclusive evidence. Other treatments
for which there is inconclusive evidence include
aerobic exercise, stress reduction, cognitive
therapy, spironolactone, magnesium, nonsteroidal
anti-inflammatory drugs, various hormonal regimens,
and a complex carbohydrate-rich diet. Although
evidence for them is inconclusive, it is reasonable
to recommend healthy lifestyle changes given their
overall health benefits. Progesterone and bromocriptine,
which are still widely used, are ineffective.
CONCLUSION: Calcium carbonate should be recommended as first-line
therapy for women with mild-to-moderate PMS. Selective serotonin reuptake inhibitors can be
considered as first-line therapy for women with
severe affective symptoms and for women with milder
symptoms who have failed to respond to other therapies.
Other therapies may be tried if these measures
fail to provide adequate relief.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
| Abstracts
on Magnesium |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Panminerva Med. 2001 Sep;43(3):177-209.
Hypomagnesemia.
A review of pathophysiological, clinical and therapeutical
aspects.
Iannello S, Belfiore
F.
Institute of Internal Medicine
and Internal Specialties, Chair of Internal Medicine,
University of Catania Medical School, Garibaldi
Hospital, Catania, Italy. francesco.belfiore@iol.it
The aim of this paper is to
discuss, on the basis of an extensive literature
review, the role of magnesium (Mg) in health and
disease. Mg is an essential cation playing a crucial
role in many enzyme systems. Quantitative Mg body
stores are regulated by metabolic and hormonal
effects on gastrointestinal absorption and renal
excretion. Mg is a smooth muscle relaxant, dilates
coronary arteries and peripheral vessels, exerts
antiarrhythmic effects, may have a permissive
effect on catecholamine actions and can play a
role in various thrombogenic conditions. Today,
hypomagnesemia has become a recognized medical
occurrence which may be associated with many different
diseases, either genetic or acquired. Mg
deficiency is one of the most frequent electrolyte
abnormalities in clinical practice, but it is
probably the most underdiagnosed one. Clinical
manifestations of hypomagnesemia may begin insidiously
or dramatically sudden. A large part of the population
(especially aged subjects) may have an inadequate
Mg intake and a chronic latent Mg deficiency.
Routine inclusion of serum Mg analysis in the
electrolyte panel represents a continued need
to recognize hypomagnesemia and to treat Mg-depleted
patients. New clinical studies on Mg deficiency
are necessary to ascertain the usefulness and
cost-effectiveness of Mg replacement therapy.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
South Med J. 2001 Dec;94(12):1195-201.
Comment in:
• South Med J. 2003 Jan;96(1):104.
Magnesium:
its proven and potential clinical significance.
Fox C, Ramsoomair
D, Carter C.
Department of Family Medicine,
State University of New York at Buffalo, 14215,
USA.
Magnesium is the fourth most
abundant cation in the body and is present in
more than 300 enzymatic systems, where it is crucial
for adenosine triphosphate (ATP) metabolism. Deficiency
states result in increased insulin resistance,
as well as increased smooth muscle and platelet
reactivity. Magnesium
deficiency has been shown to correlate with a
number of chronic cardiovascular diseases, including
hypertension, diabetes mellitus, and hyperlipidemia.
Intravenous magnesium has been used therapeutically
in critical situations such as status asthmaticus,
torsades de pointes, and preeclampsia. Few controlled studies exist regarding the therapeutic
uses of oral magnesium supplementation in chronic
cardiovascular diseases. Randomized clinical trials
are urgently needed to determine whether magnesium
supplementation will alter the natural history
of these disease states.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
New Horiz. 1994 May;2(2):186-92.
Should
we supplement magnesium in critically ill patients?
Olerich MA, Rude
RK.
Department of Diabetes,
Los Angeles County/University of Southern California
Medical Center 90033.
Magnesium (Mg) deficiency is
a common yet underdiagnosed problem in the ICU.
Since only 1% of total body Mg is in the extracellular
fluid, serum Mg concentrations may not adequately
reflect Mg status. Utilizing techniques to measure intracellular
Mg concentrations, Mg depletion has been shown
to be present in about one half of all ICU patients.
These patients have significantly higher morbidity
and mortality rates than Mg-replete patients. Accurate identification of patients with Mg depletion
requires a knowledge of the risk factors associated
with Mg deficiency. These factors include poorly
controlled diabetes mellitus, alcohol ingestion,
severe diarrhea and steatorrhea, and the use of
a number of pharmacologic agents that induce renal
Mg wasting. Manifestations of Mg deficiency include
hypokalemia, hypocalcemia, neuromuscular hyperexcitability,
respiratory muscle weakness, and intractable arrhythmias.
Mg deficiency may also play a role in the genesis
of myocardial ischemia. In this article, we review
the assessment, causes, and manifestations of
Mg deficiency and suggest guidelines for adequate
treatment.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Dis Mon. 1988 Apr;34(4):161-218.
Magnesium
metabolism in health and disease.
Elin RJ.
Clinical Pathology Department,
National Institutes of Health, Bethesda, Maryland.
Magnesium is an important element
for health and disease. Magnesium, the second
most abundant intracellular cation, has been identified
as a cofactor in over 300 enzymatic reactions
involving energy metabolism and protein and nucleic
acid synthesis. Approximately half of the total
magnesium in the body is present in soft tissue,
and the other half in bone. Less than 1% of the
total body magnesium is present in blood. Nonetheless,
the majority of our experimental information comes
from determination of magnesium in serum and red
blood cells. At present, we have little information
about equilibrium among and state of magnesium
within body pools. Magnesium is absorbed uniformly
from the small intestine and the serum concentration
controlled by excretion from the kidney. The clinical
laboratory evaluation of magnesium status is primarily
limited to the serum magnesium concentration,
24-hour urinary excretion, and percent retention
following parenteral magnesium. However, results
for these tests do not necessarily correlate with
intracellular magnesium. Thus, there is no readily
available test to determine intracellular/total
body magnesium status. Magnesium deficiency may
cause weakness, tremors, seizures, cardiac arrhythmias,
hypokalemia, and hypocalcemia. The causes of hypomagnesemia
are reduced intake (poor nutrition or IV fluids
without magnesium), reduced absorption (chronic
diarrhea, malabsorption, or bypass/resection of
bowel), redistribution (exchange transfusion or
acute pancreatitis), and increased excretion (medication,
alcoholism, diabetes mellitus, renal tubular disorders,
hypercalcemia, hyperthyroidism, aldosteronism,
stress, or excessive lactation). A
large segment of the U.S. population may have
an inadequate intake of magnesium and may have
a chronic latent magnesium deficiency that has
been linked to atherosclerosis, myocardial infarction,
hypertension, cancer, kidney stones, premenstrual
syndrome, and psychiatric disorders. Hypermagnesemia
is primarily seen in acute and chronic renal failure,
and is treated effectively by dialysis.
|
 |
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |